ESMO 2018 Prostate Cancer - Results from #20

Viewing 21-37 of 37 articles

ESMO 2018: Radiotherapy to the Primary Tumour for Men with Newly-Diagnosed Metastatic Prostate Cancer: Survival Results from STAMPEDE

ESMO 2018: Tobacco Control: Saving Lives and Driving Development

ESMO 2018: Cancer Awareness and Screening: The Challenges

ESMO 2018: LATITUDE: PSA Response Characteristics and Correlation with Overall Survival and Radiological Progression-Free Survival

ESMO 2018: Why We are Losing the War on Cancer

ESMO 2018: Preliminary Results From TRITON2: A Phase II Study of Rucaparib in Patients with mCRPC Associated with Homologous Recombination Repair Gene Alterations

ESMO 2018: The Surgical Approach for Malignant Pheochromocytoma / Paraganglioma

ESMO 2018: Pillars of an Effective Healthcare System in Europe, Special Focus on Healthcare in Central and Eastern Europe

ESMO 2018: Pillars of an Effective Healthcare System in Europe Key Components of a Well-Functioning Healthcare System

ESMO 2018: When is a Cancer Patient Cured?

ESMO 2018: The Right to be Forgotten - Access to Loan-Related Insurance for French Cancer Survivors

ESMO 2018: 12-Year Follow-Up of GETUG-12, A Phase 3 Trial of Docetaxel-Based Chemotherapy in High-Risk Localized Prostate Cancer

ESMO 2018: Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Bone-Predominant mCRPC

ESMO 2018: ERA 223 - A Phase 3 Trial of Ra-223 in Combination with Abiraterone Acetate & Prednisone for the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with mCRPC

ESMO 2018: Cabazitaxel vs Abiraterone or Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer Patients

ESMO 2018: A Randomized Phase 2 Study of Cabazitaxel vs Abiraterone or Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer

ESMO 2018: Updated Results of GETUG-12, a Phase III Trial Of Docetaxel-Based Chemotherapy In High-Risk Localized Prostate Cancer, with a 12-Year Follow-Up

1
2